Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India's Lupin has reported that the FDA has approved the company's higher concentration formulation of its children's antibiotic Suprax Cefixime.
Subscribe to our email newsletter
The reformulation of Suprax allows parents to administer fewer teaspoons per dose of the antibiotic to their children. When using the novel dose, parents would need to administer only half the volume of the existing 100mg/5ml suspension.
Dr Kamal Sharma, managing director of Lupin, said: “The incidence of respiratory infections is high in children and physicians need products that offer greater patient convenience and compliance.”
The US pediatric antibiotic market is currently valued at $625 million, according to the company.